| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.13 | 3e-05 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.12 | 3e-05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.11 | 5e-05 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.13 | 6e-05 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.12 | 6e-05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.12 | 6e-05 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | -0.12 | 7e-05 |